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Abstract
Background: Prior pregnancy is known to protect against development of breast cancer. Recent studies have demonstrated
that pregnancy has the capacity to establish small numbers of immunologically active fetal-derived cells in the mother, a
phenomenon known as fetal microchimerism (FMc). We asked whether presence of FMc, routinely acquired during
pregnancy, is a protective factor for breast cancer.
Methodology/Principal Findings: DNA extracts from peripheral blood specimens were obtained from a population-based
case-control study of risk factors for breast cancer in women 21 to 45 years old. Specimens were tested with quantitative
PCR for presence and concentrations of male DNA presumed to derive from prior pregnancies with a male fetus. Odds ratios
(OR) and 95% confidence intervals (CI) were estimated with consideration of multiple established reproductive and
environmental risk factors for breast cancer. FMc results were generated on 99 parous women, 54 with primary invasive
breast cancer and 45 general population controls. FMc prevalence was 56% (25/45) and 26% (14/54) in controls and cases,
respectively. Women harboring FMc were less likely to have had breast cancer (OR=0.29, 95% CI 0.11–0.83; p=0.02,
adjusting for age, number of children, birth of a son, history of miscarriage, and total DNA tested). In addition, FMc
concentrations were higher in controls versus cases (p=0.01). Median concentrations were 2 (0–78) and 0 (0–374) fetal
genomes/10
6 maternal genomes in controls and cases, respectively.
Conclusions: Results suggest that the enigma of why some parous women are not afforded protection from breast cancer
by pregnancy might in part be explained by differences in FMc. Mechanistic studies of FMc-derived protection against
breast cancer are warranted.
Citation: Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL (2008) Case-Control Study of Fetal Microchimerism and Breast Cancer. PLoS ONE 3(3): e1706.
doi:10.1371/journal.pone.0001706
Editor: Mikhail V. Blagosklonny, Ordway Research Institute, United States of America
Received December 10, 2007; Accepted February 4, 2008; Published March 5, 2008
Copyright:  2008 Gadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by a research grant AI41721 from the National Institutes of Health (JLN). The funding source had no role in the design of the
studies presented, in the collection or presentation of data, in the writing of the manuscript, or in the decision to submit this manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vkgadi@u.washington.edu
Introduction
Risk modifiers for development of breast cancer are both
genetic and environmental. The known germline genetic risk
modifiers identified thus far are few (e.g., BRCA1 and BRCA2)
and overall account for only 2–10% of all cases [1–3].
Environmental risk modifiers including but not limited to
reproductive factors, endogenous and exogenous hormones,
anthropometric characteristics, and certain lifestyle factors are
known to impact a woman’s risk for breast cancer development.
Mechanisms underlying these effects are still largely unclear and
under active investigation. A prior history of pregnancy has been
noted as a consistent protective factor in breast cancer but the
magnitude of this reduced risk is relatively modest [4,5]. Thus, it is
conceivable that there are undefined characteristics of prior
pregnancies that could underlie why some parous women
experience a reduced risk of breast cancer while others do not.
We and others have shown that a natural consequence of
normal pregnancy is the acquisition and stable persistence of small
numbers of fetal cells in the mother’s body, a phenomena known
as fetal microchimerism (FMc) [6–9]. FMc has been identified in
the peripheral blood within subsets of immune cells [7,8].
Although the specific effects or consequences of FMc remain to
be demonstrated in healthy women, FMc has been implicated in
‘‘alloimmunity’’ in some classically autoimmune diseases, for
example systemic sclerosis and thyroiditis [8,10–12]. One possible
role of FMc in healthy women might be the provision of allogeneic
immune surveillance for (pre-)malignant cells. Allogeneic cells,
particularly mismatched or haploidentical cells, in the context of
hematopoietic transplantation have been found to provide potent
immune surveillance for both hematologic and solid tumor
malignancies in a process referred to as graft-versus-tumor [13–
15]. By integrating the aforementioned observations of FMc in
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that allogeneic FMc might provide immune surveillance for breast
cancer in parous women. In a prospective, pilot study we
previously identified a decreased prevalence of FMc in the
peripheral blood mononuclear cells of parous women with breast
cancer compared to controls [16]. We demonstrate here in a
larger case-control study that women with breast cancer are
deficient both by presence and quantity of FMc in the peripheral
blood compared to carefully matched controls. This finding
supports the hypothesis that parous women with breast cancer fail
to harbor a potential source of naturally acquired allogeneic
immunity.
Methods
Specimens
Specimens tested for FMc were obtained from women residing
in the three county Puget Sound region of Western Washington
State who previously participated in a population-based case-
control study of breast cancer in women aged 21–44. The methods
for this study have been described [17]. Briefly, cases (women with
a first primary invasive breast cancer) were ascertained through
the Cancer Surveillance System, a population based-cancer
registry. Control participants (women without breast cancer) were
identified by random-digit dialing in the same region and
frequency matched for age. All participants completed an in-
person structured interview detailing family, environmental, and
reproductive histories and provided a peripheral blood specimen.
Informed consent from participants of the parent study was
documented with consent forms approved by the Fred Hutchinson
Cancer Research Center Institutional Review Board. Samples
from the larger case-control study included in this study were
selected from women with non-metastatic disease, a history of at
least one completed pregnancy, and no chemotherapy exposure
before study phlebotomy.
For the current study, 100 participants were tested for FMc.
One woman was excluded from final analysis because correlative
clinical data for reproductive factors was not available. Altogether,
54 cases and 45 controls were evaluable for FMc.
Procedures
FMc was identified and quantified in genomic DNA extracted
from peripheral blood buffy coat specimens employing quantita-
tive PCR for a Y chromosome specific gene, DYS14. Male DNA is
assumed to derive from prior pregnancy with a male fetus. The
approach permitted comparison of cases to controls while
recognizing that the overall prevalence of FMc is underestimated
as FMc from female fetuses could not be assessed. The method for
testing male FMc using quantitative PCR has been previously
described [7]. Testing for FMc was performed by a female
technician (to minimize contamination from male DNA) blinded
to the case-control status of the specimens. In brief, six aliquots of
DNA from each specimen were tested for DYS14. Quantitative
PCR reactions were performed on an ABI Prism 7000 running the
manufacturer’s software (SDS v1.2.3). Results from each aliquot
were plotted by the software onto a simultaneously run calibration
curve generated from known quantities of DYS14. An additional 2
aliquots from each specimen were tested for the beta-globin gene
(present in two copies per cell) with results plotted similarly on a
beta-globin calibration curve to provide an estimate of the total
number of cells tested. After using a correction factor of 6.6pg of
DNA per cell [18], data were expressed as a ratio of male (fetal)
genome equivalents per 10
6 host (maternal) genome equivalents. A
minimum of 3.0610
4 genomes were tested in all 6 wells combined
to insure sufficient material was examined for FMc. A maximum
of 3.0610
4 genomes were tested in any single well because of PCR
inhibition when greater input DNA is used. All wells read positive
for DYS14 sequence by the software were confirmed by individual
amplification analysis in a blinded manner by one of the authors
(VKG). For a specimen to be considered positive for FMc, a
minimum of two wells were required to have surpassed the
detection threshold for amplification.
Table 1. Baseline characteristics of breast cancer cases and
controls
Cases (54) Controls (45)
N( % ) N( % )
Race
Caucasian/Hispanic 48 (89) 41 (91)
Other 6 (11) 4 (9)
Median age in years (range) 41 (35–44) 41 (31–44)
Smoking status
Never 30 (56) 23 (51)
Former 8 (15) 9 (20)
Current 16 (30) 11 (24)
Unknown 0 2 (4)
Age at first birth (years)*
,20 9 (17) 12 (27)
20–29 31 (57) 29 (64)
$30 14 (26) 4 (9)
Number of children
1 13 (24) 12 (27)
2 24 (44) 18 (40)
3 or more 17 (32) 15 (33)
Gave birth to a son 42 (78) 32 (71)
At least one pregnancy loss
{ 29 (54) 21 (47)
Number of miscarriages
0 35 (65) 33 (73)
1 12 (22) 8 (18)
2 or more 7 (13) 4 (9)
Number of abortions
0 40 (74) 32 (71)
1 10 (19) 8 (18)
2 or more 4 (7) 5 (11)
Breastfed at least 2 weeks
No 13 (24) 14 (31)
Yes 41 (76) 31 (69)
Age at menarche (years)
8–12 27 (50) 18 (40)
.13 27 (50) 27 (60)
Duration oral contraception use (years)
{
,1 6 (11) 14 (31)
1–4 24 (44) 14 (31)
$5 24 (44) 17 (38)
*Age at first birth older in cases than in controls (p=0.03);
{Pregnancy loss includes miscarriage, abortion, tubal pregnancy and stillbirth;
{Exposure to oral contraception greater in cases than in controls (p=0.04).
doi:10.1371/journal.pone.0001706.t001
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The primary outcome for analysis was disease status (breast
cancer case vs. control) and the principal predictor of interest was
the presence of FMc. Factors examined as potential confounders
or effect modifiers included age (at breast cancer diagnosis for
cases, at time of study enrollment for controls), age at first birth,
number of children, birth of a son, history of breastfeeding,
miscarriage, abortion, oral contraceptive use, smoking status, age
at menarche and number of cell equivalents tested for detection of
FMc. A factor was defined as a confounder if there was a
discrepancy of 10% or more in the estimated coefficient of interest
between the multivariable model including the factor and the
model without it. Differences in subject characteristics between
groups were assessed via t-test for continuous variables and Chi-
squared test for categorical factors. Logistic regression models were
used to estimate the association between presence of FMc and
disease status, while adjusting for age and other confounding
factors.
FMc concentrations were further analyzed according to disease
status. FMc concentrations were ranked and the ranks were used
as the outcome for linear regression models to account for
departures from normality in the distribution of the FMc values.
Such transformation of the data preserves the ordering of values
and gives estimates that are less sensitive to outlying values;
however, model coefficients are no longer interpretable in terms of
actual FMc values. The linear regression models were adjusted for
age and other confounders.
Additional analyses were conducted to examine whether breast
cancer-specific features were associated with FMc prevalence
among the cases. Presence of FMc was treated as a binary
outcome in logistic regression models, with age at diagnosis and
various disease characteristics as the predictors. P-values from
regression models were derived from the Wald test, and no
adjustments were made for multiple comparisons. Analyses were
performed on SAS software version 8 (SAS Institute, Inc., Cary,
NC).
Results
Baseline characteristics of breast cancer patients and control
participants are shown in Table 1. The two groups did not differ
with respect to most characteristics considered. Women diagnosed
with breast cancer, however, were significantly older at the time
they first gave birth (p=0.03), an observation consistent with the
original analysis of this case-control study [7]. Women with breast
cancer were also more likely to have used oral contraception
(p=0.04) than control women.
Overall, FMc was found in 39 women, including 25 of 45
controls (56%) and 14 of 54 breast cancer patients (26%). Table 2
shows the prevalence of FMc and the association of FMc and risk
of breast cancer. Compared to women who were FMc-negative,
women harboring FMc were significantly less likely to have had
breast cancer (OR=0.20, 95% CI 0.08–0.53; p=0.001, adjusting
for age, number of children, birth of a son and history of
miscarriage). The total number of cell equivalents tested for
detection of FMc was higher in the controls than in the breast
cancer cases (mean 8.26104 (95% CI 7.2–9.2610
4) in controls
versus 5.66104 (95% CI 4.9–6.3610
4) in cases). This factor acted
as a moderate confounder, slightly diminishing the effect of FMc in
the final model (OR=0.29, 95% CI 0.11–0.83; p=0.02).
Concentrations of FMc in peripheral blood in women with and
without breast cancer are depicted in Figure 1. Median
concentrations were 2.0 versus 0 FMc cells per million maternal
cells in healthy women and breast cancer patients, respectively.
FMc concentrations were significantly higher in the controls than
in the women with history of breast cancer (p=0.01) in a model of
the ranked values adjusted for age, number of children, birth of a
Table 2. Risk of breast cancer and FMc
Presence
of FMc
Proportions by
Disease Status OR (95% CI) p
No. Cases
(%)
No. Controls
(%)
No 40 (74) 20 (54) 1.0 –
Yes 14 (26) 25 (56) 0.20(0.08–0.53) 0.001
*
0.29 (0.11–0.83) 0.02
**
*Adjusted for age, number of children, birth of a son, history of miscarriage;
**adjusted for above and total number of cell equivalents tested.
doi:10.1371/journal.pone.0001706.t002
Figure 1. FMc concentrations in peripheral blood buffy coat (fetal genomes per 10
6 maternal genomes). Median FMc concentrations
were 2 (0–78) and 0 (0–375) in controls and cases, respectively. Two outlying values among the cases (277 and 374) are shown truncated.
doi:10.1371/journal.pone.0001706.g001
Microchimerism and Cancer
PLoS ONE | www.plosone.org 3 March 2008 | Volume 3 | Issue 3 | e1706son, history of miscarriage, oral contraceptive use, and total
number of genomes tested.
Among cases, analyses were conducted to examine whether
breast cancer specific features were associated with FMc
prevalence (Table 3). The results suggest that women without
FMc were more likely to have advanced disease features than
women with FMc although none of these associations achieved
statistical significance.
Discussion
In this case-control study of breast cancer among parous
women, women with breast cancer were more frequently deficient
in FMc when compared to control women. Both overall
prevalence and quantity of FMc were significantly different
between parous women with and without breast cancer. Other
known risk modifiers for breast cancer such as age at first
pregnancy, history of oral contraceptive use, breast feeding, and
smoking did not meaningfully confound the overall association of
FMc absence with breast cancer. Furthermore, in case-only
analyses, women with adverse breast cancer features (for example,
higher stage or hormone receptor negativity) consistently had
lower prevalence of FMc although no single characteristic reached
statistical significance because power was limited for such analyses.
In prior pilot studies we similarly found a decreased prevalence
of FMc in women with breast cancer [16]. When comparing the
current data to our prior pilot study, the current data strengthens
the overall inverse association of FMc and breast cancer. First, the
study here considers more cases for analysis and permitted both
examination of proportions and quantities of FMc when compared
to the prior pilot study. The current findings replicate the principal
finding of the pilot and add to it by demonstrating a difference in
FMc concentrations between cases and controls. Second, because
we utilized specimens from a matched case-control study,
reproductive and other risk factors were more similar than in
the prior pilot and allowed for multivariable modeling to adjust for
any potential confounders.
When comparing the current data to prior studies of FMc, some
additional differences merit discussion. FMc results could vary
depending on the compartment of blood tested. Most prior studies
of FMc examined Ficoll-purified peripheral blood mononuclear
cells. To our knowledge, there are no studies of FMc in buffy coat.
The overall prevalence and concentrations of FMc in controls
described here were somewhat higher when compared to findings
from Ficoll-purified cells. The key constituents more greatly
represented in buffy coat compared to Ficoll-purified cells are
large granular cells such as neutrophils or dendritic cells. Our data
then indirectly suggest that FMc in healthy women might be
represented in cells that are part of the innate immune response
and/or in cells involved in antigen presentation. Second, in prior
work, we have been able to employ an extensive panel of allelic
quantitative PCR assays to catalog all potential sources of FMc
regardless of sex of the child [19]. We did not have access to
samples from children of probands in the current study for the
purpose of polymorphism typing to identify informative assays for
all potential FMc. On the other hand, control women and women
with breast cancer were similar for having given birth to children
of either sex and for total number of children.
The protection from breast cancer afforded by parity is
incomplete. We provide data that suggest there is a failure to
acquire or maintain allogeneic immune cells (FMc) transmitted
from the fetus to the mother during pregnancy in women who
develop breast cancer. These allogeneic cells have the potential to
participate in immune surveillance for breast or other cancers as
observed in clinical hematopoietic stem cell transplantation.
Additional studies are required to identify the specific mechanisms
by which FMc could participate in the protection from breast or
other cancers. Knowledge gained from mechanistic studies may
contribute to the design of allogeneic vaccine-based or adoptive
immunotherapy for breast cancer. We acknowledge that replica-
tion of our findings in larger study populations is required because
the sample size is small. Nonetheless, if our results are replicated,
testing for FMc could be used to identify healthy women who
might be at risk for developing breast cancer. Finally, the work
presented here is of potential interest to evolutionary biologists as it
provides additional support in human females for the concept of
long-term fitness benefit through reproduction.
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Table 3. Prevalence and odds of harboring FMc according to
disease characteristics
FMc (14) No FMc (40) Adjusted*
N (%) N (%) OR (95% CI)
AJCC
{ stage
I 11 (33) 22 (67) 1.0
IIA or higher 3 (14) 18 (86) 3.1 (0.7–14.3)
Tumor size (cm)
#2 12 (30) 28 (70) 1.0
2–5 2 (17) 10 (83) 1.7 (0.3–9.7)
{
.5 0 2 (100) –
Nodal status
Negative 11 (29) 27 (71) 1.0
Positive 3 (19) 13 (81) 2.1 (0.4–9.8)
Estrogen receptor
Positive 13 (29) 32 (71) 1.0
Negative 1 (11) 8 (89) 6.6 (0.6–73.5)
Progesterone receptor
Positive 14 (31) 31 (69) –
1
Negative 0 9 (100) –
1
Average ratio of Ki-67
0–24% 13 (30) 30 (70) 1.0
25–100% 1 (9) 10 (91) 3.1 (0.3–28.3)
C-erbB-2
Negative 7 (26) 20 (74) 1.0
Positive 7 (26) 20 (74) 1.5 (0.4–5.7)
Histology
Ductal 12 (27) 32 (73) 1.0
Other 2 (20) 8 (80) 1.1 (0.2–6.6)
Histology grade
Low 6 (38) 10 (62) 1.0
Intermediate or High 8 (22) 28 (78) 2.1 (0.5–8.3)
*Adjusted for age at diagnosis;
{AJCC=American Joint Committee on Cancer;
{Tumor sizes of 2–5 and .5 cm combined for comparison to #2c m ;
1Odds ratio cannot be calculated.
doi:10.1371/journal.pone.0001706.t003
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